We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+0.23%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.56B
AUM Growth
-$299M
Cap. Flow
+$625M
Cap. Flow %
8.26%
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$134M
2
CLYM
Climb Bio
CLYM
+$122M
3
ACLX
Arcellx
ACLX
+$87.2M
4
EVH icon
Evolent Health
EVH
+$71M
5
RNAM
Avidity Biosciences
RNAM
+$60.8M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$91.9M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$54.6M
3
CTKB icon
Cytek Biosciences
CTKB
+$45.7M
4
VXRT
Vaxart
VXRT
+$20M
5
EYPT icon
EyePoint Inc
EYPT
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMSW icon
76
NewAmsterdam Pharma Warrant
NAMSW
$2.91M 0.04%
333,333
– –
UNCY icon
77
Unicycive Therapeutics
UNCY
$137M
$1.32M 0.02%
263,220
-83,849
-24% -$824K
SCLX icon
78
Scilex Holding
SCLX
$46.9M
$504K 0.01%
+7,462
New +$315K
BDTX icon
79
Black Diamond Therapeutics
BDTX
$96.8M
– –
-3,525,754
Closed -$17.9M
CMPS
80
Compass Pathways
CMPS
$1.53B
– –
-791,359
Closed -$6.58M
CTKB icon
81
Cytek Biosciences
CTKB
$545M
– –
-6,809,404
Closed -$45.7M
CVAC
82
DELISTED
CureVac
CVAC
– –
-1,965,707
Closed -$5.96M
EYPT icon
83
EyePoint Inc
EYPT
$1.03B
– –
-938,591
Closed -$19.4M
IGMS
84
DELISTED
IGM Biosciences
IGMS
– –
-937,500
Closed -$9.05M
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-204,500
Closed -$54.6M
VXRT
86
DELISTED
Vaxart
VXRT
– –
-15,384,615
Closed -$20M
INBX
87
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-2,629,837
Closed -$91.9M
1 2 3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, RA Capital Management held 87 positions worth $7.56B, down 3.8% from $7.86B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RA Capital Management deployed $625M of net new capital in Q2 2024, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was iTeos Therapeutics, an estimated $12.9M trimmed.

  • RA Capital Management's largest Q2 2024 buy was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.
  • RA Capital Management added most to Climb Bio in Q2 2024, an estimated $122M increase.
  • RA Capital Management's biggest Q2 2024 reduction was iTeos Therapeutics, cutting an estimated $12.9M.
  • RA Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $91.9M.
  • RA Capital Management's ten largest holdings make up 54% of its $7.56B portfolio in Q2 2024.
  • RA Capital Management opened 11 new positions and closed 9 in Q2 2024.
  • RA Capital Management's portfolio value fell 3.8% quarter-over-quarter to $7.56B.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.